Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. [electronic resource]
Producer: 20111024Description: 3351-7 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Carcinoma, Ductal, Breast -- drug therapy
- Carcinoma, Lobular -- drug therapy
- Chemotherapy, Adjuvant
- Cohort Studies
- Cyclophosphamide -- administration & dosage
- Epirubicin -- administration & dosage
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Invasiveness
- Paclitaxel -- administration & dosage
- Prospective Studies
- Receptor, ErbB-2 -- metabolism
- Remission Induction
- Survival Rate
- Trastuzumab
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.